Table 3.
FDA-approved CAR-T therapies
| Drug/company | Year approved | Target | Number of approvals |
|---|---|---|---|
| Carvykti (ciltacabtagene autoleucel)/Johnson & Johnson | 2022 | B cell maturation antigen | 1 |
| Abecma (idecabtagene vicleucel)/Bristol Myers Squibb | 2021 | B cell maturation antigen | 1 |
| Breyanzi (lisocabtagene maraleucel)/Bristol Myers Squibb | 2021 | CD19 | 2 |
| Tecartus (brexucabtagene autoleucel)/Gilead Sciences | 2021 | CD19 | 2 |
| Yescarta (axicabtagene ciloleucel)/Gilead Sciences | 2017 | CD19 | 2 |
| Kymriah (tisagenlecleucel)/Novartis | 2017 | CD19 | 3 |